BRPI0913410A2 - uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica - Google Patents

uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica

Info

Publication number
BRPI0913410A2
BRPI0913410A2 BRPI0913410A BRPI0913410A BRPI0913410A2 BR PI0913410 A2 BRPI0913410 A2 BR PI0913410A2 BR PI0913410 A BRPI0913410 A BR PI0913410A BR PI0913410 A BRPI0913410 A BR PI0913410A BR PI0913410 A2 BRPI0913410 A2 BR PI0913410A2
Authority
BR
Brazil
Prior art keywords
nanoparticle
pharmaceutical composition
aggregate
nanoparticle aggregate
pharmaceutical
Prior art date
Application number
BRPI0913410A
Other languages
English (en)
Inventor
Agnès Pottier
Annabelle Rouet
Corinne Devaux
Julie Marill
Laurent Levy
Matthieu Germain
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of BRPI0913410A2 publication Critical patent/BRPI0913410A2/pt
Publication of BRPI0913410B1 publication Critical patent/BRPI0913410B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0913410-7A 2008-06-05 2009-06-04 Uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica BRPI0913410B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08157686.0 2008-06-05
EP08157686A EP2130553A1 (en) 2008-06-05 2008-06-05 Inorganic nanoparticles of high density to destroy cells in-vivo
US6020208P 2008-06-10 2008-06-10
US61/060202 2008-06-10
PCT/EP2009/056880 WO2009147214A2 (en) 2008-06-05 2009-06-04 Inorganic nanoparticles, preparation and uses thereof

Publications (2)

Publication Number Publication Date
BRPI0913410A2 true BRPI0913410A2 (pt) 2015-11-24
BRPI0913410B1 BRPI0913410B1 (pt) 2021-09-21

Family

ID=39734334

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913410-7A BRPI0913410B1 (pt) 2008-06-05 2009-06-04 Uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica

Country Status (26)

Country Link
US (1) US8845507B2 (pt)
EP (4) EP2130553A1 (pt)
JP (1) JP5734181B2 (pt)
KR (1) KR101639281B1 (pt)
CN (1) CN102056628B (pt)
AU (1) AU2009254550B2 (pt)
BR (1) BRPI0913410B1 (pt)
CA (1) CA2727576C (pt)
CY (2) CY1118217T1 (pt)
DK (2) DK2300054T3 (pt)
EA (1) EA023012B1 (pt)
ES (2) ES2702249T3 (pt)
HR (2) HRP20161465T8 (pt)
HU (2) HUE030669T2 (pt)
IL (1) IL209625A (pt)
LT (2) LT3150227T (pt)
MA (1) MA32453B1 (pt)
MX (1) MX2010013322A (pt)
NZ (1) NZ589888A (pt)
PL (2) PL3150227T3 (pt)
PT (2) PT3150227T (pt)
SG (1) SG10201405288WA (pt)
SI (2) SI3150227T1 (pt)
TR (1) TR201819077T4 (pt)
WO (1) WO2009147214A2 (pt)
ZA (1) ZA201100082B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070164238A1 (en) * 2003-02-24 2007-07-19 Pomper Mark E Mobile radiation treatment vehicle and method
US8459714B2 (en) 2006-05-19 2013-06-11 Breya, Llc. Mobile radiation therapy
US8657354B2 (en) 2006-05-19 2014-02-25 Breya, Llc. Mobile radiation therapy
US8728440B2 (en) 2012-08-23 2014-05-20 General Electric Company Nanoparticulate compositions for diagnostic imaging
US9399075B2 (en) 2008-12-29 2016-07-26 General Electric Company Nanoparticle contrast agents for diagnostic imaging
US9585840B1 (en) 2009-07-10 2017-03-07 University Of Central Florida Research Foundation, Inc. Redox active cerium oxide nanoparticles and associated methods
EP2275137A1 (en) * 2009-07-10 2011-01-19 Nanobiotix Metallic nanoparticles, preparation and uses thereof
CN107149689A (zh) 2009-11-10 2017-09-12 免疫之光有限责任公司 对可辐射固化介质进行固化的系统和产生光的方法
US8592511B2 (en) 2010-04-23 2013-11-26 Pixelligent Technologies, Llc Synthesis, capping and dispersion of nanocrystals
CN107416764A (zh) 2010-10-27 2017-12-01 皮瑟莱根特科技有限责任公司 纳米晶体的合成、盖帽和分散
US9359689B2 (en) 2011-10-26 2016-06-07 Pixelligent Technologies, Llc Synthesis, capping and dispersion of nanocrystals
AU2012351537B2 (en) 2011-12-16 2017-03-02 Nanobiotix Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof
US20150141875A1 (en) * 2012-06-14 2015-05-21 The Board Of Trustees Of The University Of Arkansas Compositions and methods for non-invasive detection and treatment of hypoxic cells in vivo
US8821838B2 (en) 2012-08-23 2014-09-02 General Electric Company Nanoparticulate compositions for diagnostic imaging
US10098952B2 (en) * 2013-01-25 2018-10-16 Nanobiotix Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer
BR112015019949A2 (pt) * 2013-02-19 2017-08-29 National Health Res Inst Nanoclusters de platina confinada para quimioterapias anticancerígenas
JP6387400B2 (ja) 2013-05-30 2018-09-05 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 医薬組成物、その製造および使用
WO2014202723A1 (en) * 2013-06-20 2014-12-24 Nanobiotix Compositions and methods for use in medical diagnosis
EP2886128A1 (en) * 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
NZ769187A (en) 2014-11-25 2023-07-28 Curadigm Sas Pharmaceutical composition, preparation and uses thereof
HUE062561T2 (hu) 2014-11-25 2023-11-28 Curadigm Sas Legalább két eltérõ nanorészecskéket és egy gyógyászati vegyületet kombináló gyógyászati készítmény, annak elõállítása és alkalmazásai
TW201628644A (zh) 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備及其用途
PT3223796T (pt) 2014-11-25 2021-09-28 Curadigm Sas Composições farmacêuticas, preparação e suas utilizações
TW201628639A (zh) 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備及其用途
EP3242670B1 (en) * 2015-01-08 2020-06-24 Purdue Research Foundation Non-toxic formulations of radio-luminescent nanoparticles for use as cancer radio-sensitizing agents
WO2016189125A1 (en) 2015-05-28 2016-12-01 Nanobiotix Nanoparticles for use as a therapeutic vaccine
US11389536B2 (en) 2015-07-17 2022-07-19 BioCurity Pharmaceuticals Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
CN109010828B (zh) * 2018-10-12 2020-10-20 中国科学院高能物理研究所 一种二硫化钼/二氧化铪的复合纳米材料、其制备方法及用途
CN109616308B (zh) * 2018-11-07 2020-09-04 湖北第二师范学院 一种球形纳米氧化铱dna提取磁性粉末及其生产方法
CN109771645B (zh) * 2019-03-07 2021-08-24 广西师范大学 一种二氧化钌复合卵清蛋白纳米材料的制备及其应用
EP4157457A1 (en) * 2020-05-26 2023-04-05 Nanobiotix Nanoparticles, ionizing radiation and innovative therapeutic combinations thereof
AU2021374754A1 (en) * 2020-11-05 2023-06-22 Nanobiotix Compositions of nanoparticles for treatment of cancer
EP4255488A1 (en) * 2020-12-01 2023-10-11 Nanobiotix Porous, high-z and carbon-free particles as radioenhancers
WO2024126383A1 (en) 2022-12-12 2024-06-20 Nanobiotix (Nanobiotix S.A.) Novel metal oxide nanoparticles and compositions thereof for use as radioenhancers or for visualizing biological tissue

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6287526A (ja) * 1985-10-11 1987-04-22 Akira Fujishima 抗腫瘍剤
WO2000006244A2 (en) 1998-07-30 2000-02-10 Hainfeld James F Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy
CN1893976A (zh) 2003-12-17 2007-01-10 皇家飞利浦电子股份有限公司 使用uv发射纳米微粒的放射治疗和医学成像
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
US20070092927A1 (en) * 2005-06-13 2007-04-26 University Of Dayton Photocatalytic particles with directed and controlled redox activity
JP2007075696A (ja) * 2005-09-13 2007-03-29 Mitsubishi Materials Corp 多孔質光触媒膜
EP2040752A2 (en) * 2006-07-10 2009-04-01 Philips Intellectual Property & Standards GmbH Core-shell nanoparticles for thearapy and imaging purposes
EP1920784A1 (en) * 2006-11-13 2008-05-14 Koninklijke Philips Electronics N.V. Radiation sensitizers in ionizing radiation therapy and imaging

Also Published As

Publication number Publication date
HRP20161465T1 (hr) 2017-01-27
CN102056628B (zh) 2013-07-10
BRPI0913410B1 (pt) 2021-09-21
EP3150227A1 (en) 2017-04-05
HRP20181993T1 (hr) 2019-01-25
CY1118217T1 (el) 2017-06-28
MX2010013322A (es) 2011-01-21
US8845507B2 (en) 2014-09-30
CA2727576A1 (en) 2009-12-10
SI3150227T1 (sl) 2019-02-28
HUE040247T2 (hu) 2019-02-28
EP2300054A2 (en) 2011-03-30
LT3150227T (lt) 2018-12-10
PT2300054T (pt) 2016-11-11
ES2702249T3 (es) 2019-02-28
HUE030669T2 (en) 2017-05-29
SI2300054T1 (sl) 2017-02-28
PT3150227T (pt) 2018-12-24
WO2009147214A2 (en) 2009-12-10
EP3461502A1 (en) 2019-04-03
US20110213192A1 (en) 2011-09-01
ZA201100082B (en) 2011-10-26
PL3150227T3 (pl) 2019-05-31
PL2300054T3 (pl) 2017-04-28
MA32453B1 (fr) 2011-07-03
ES2602048T3 (es) 2017-02-17
SG10201405288WA (en) 2014-10-30
CN102056628A (zh) 2011-05-11
WO2009147214A3 (en) 2010-02-25
HRP20161465T8 (hr) 2017-04-21
IL209625A (en) 2015-11-30
EP2130553A1 (en) 2009-12-09
EP3150227B1 (en) 2018-10-31
KR20110028616A (ko) 2011-03-21
IL209625A0 (en) 2011-02-28
KR101639281B1 (ko) 2016-07-13
NZ589888A (en) 2012-06-29
CA2727576C (en) 2016-08-16
EA201071429A1 (ru) 2011-06-30
EA023012B1 (ru) 2016-04-29
JP2011524866A (ja) 2011-09-08
EP2300054B1 (en) 2016-09-07
TR201819077T4 (tr) 2019-01-21
CY1121078T1 (el) 2019-12-11
JP5734181B2 (ja) 2015-06-17
AU2009254550B2 (en) 2013-10-24
LT2300054T (lt) 2016-12-27
AU2009254550A1 (en) 2009-12-10
DK2300054T3 (en) 2016-12-05
DK3150227T3 (en) 2019-01-14

Similar Documents

Publication Publication Date Title
BRPI0913410A2 (pt) uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica
LTPA2018014I1 (lt) Farmacinė kompozicija 514
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI0908792A2 (pt) Composição, e, uso de uma combinação
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BR112013001571A2 (pt) composto, composição farmacêutica, uso e método de prevenção ou tratamento de uma condição associada com a função do receptor gpr40
BRPI0910557A2 (pt) composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
BRPI1005931A8 (pt) associação de compostos, uso de uma associação, produto em forma de kit, uso de um produto e composição farmacêutica
BRPI1008039A2 (pt) composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0816350A2 (pt) Composições orais, produtos e métodos de uso
BRPI1013421A2 (pt) composição parasticida tópica, e, uso de uma composição
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0914793A2 (pt) Composição, e, uso de uma composição
BRPI1014316A2 (pt) composição, e, uso de uma composição
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0920355A2 (pt) composições farmacêuticas tópicas estáveis de ozenoxacina e uso de ozenoxacina
BRPI0919165A2 (pt) composição farmacêutica,e, uso de um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/06/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.